Testicular cancer--discoveries and updates.

@article{Hanna2014TesticularCA,
  title={Testicular cancer--discoveries and updates.},
  author={Nasser H Hanna and Lawrence H. Einhorn},
  journal={The New England journal of medicine},
  year={2014},
  volume={371 21},
  pages={
          2005-16
        }
}
The treatment of testicular cancer is a success story in oncology. With available methods, 95% of men with this condition can be cured. Emphasis is shifting toward maintaining high cure rates and reducing or effectively managing late effects of treatment. 

Figures and Tables from this paper

How we treat germ cell cancers
High cure rates and long-term survival for patients with germ cell cancer create an obligation to get it absolutely right. This can best be achieved by interdisciplinary teams at specialized units
Chemotherapeutic Agents for Urologic Oncology: Basic Principles
TLDR
This review will summarize chemotherapy regimens indicated for urologic cancers and their benefits.
Mediastinal germ cell tumors: new therapeutic insights.
Extragonadal germ cell tumours are rare and comprise a heterogeneous group of neoplasms with distinct natural history and responses to different treatment modalities.
Immune mechanisms and possible immune therapy in testicular germ cell tumours
TLDR
Testicular germ cell tumours are the only universally curable solid malignancy and the immunology and immunotherapy remained underinvestigated in GCTs.
Systemic Therapies in the Management of Testicular Cancers
TLDR
The aim of this chapter is to summarize systemic therapies for testicular cancer especially GCTs.
Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study
TLDR
The aim of this study was to assess the outcomes of pediatric patients with MOGCT and to achieve results with the least possible treatment‐related morbidity.
Testicular cancer: a 13‐year retrospective review of ethnic disparities in the Waikato region, New Zealand
TLDR
The testicular cancer incidence in New Zealand is rising and outcomes differed by ethnicity in NZ, but it is unclear whether this difference in outcomes is driven by race, religion, or both.
Cisplatin for testicular germ cell tumors: a rapid review
TLDR
To evaluate the effectiveness, safety and cost of cisplatin for TGCT according to the requirements of WHO EML Expert Committee, and to provide the evidence whether cis platin should be included in World Health Organization EML.
Incidentally discovered primary mediastinal germ cell tumor.
  • V. Wong, D. Geynisman
  • Medicine
    JAAPA : official journal of the American Academy of Physician Assistants
  • 2020
TLDR
A 24-year-old man with an unusual presentation for an extragonadal germ cell tumor is described.
Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin‐based therapy
To prospectively examine early hearing damage detectable with distortion product otoacoustic emission (DPOAE) after the first cycle of cisplatin treatment of patients with testicular tumor.
...
...

References

SHOWING 1-10 OF 83 REFERENCES
Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.
TLDR
A single excision is recommended for orchidectomy and adjuvant infradiaphragmatic radiotherapy for Stage 1 testicular seminoma, which occurs in early adult life and has an exce...
A nationwide cohort study of surveillance for stage I seminoma.
4502 Background: The standard treatment for stage I seminoma remains a topic for discussion. Survival rates are excellent irrespective of treatment modality (radiotherapy, carboplatin or surveillan...
Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.
TLDR
To the authors' knowledge, this is the first large population-based series reporting significantly increased risks of solid cancers among patients with testicular nonseminoma treated in the modern era of cisplatin-based chemotherapy.
High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy
TLDR
Information is provided on the potential of chemotherapy to achieve a higher chance of cure for patients with high-risk clinical stage I disease than its therapeutic alternatives and addresses toxicity and dose dependency.
Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
  • T. Tandstad, O. Dahl, O. Klepp
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
One course of adjuvant BEP reduces the risk of relapse by approximately 90% in both VASC+ and VASC- CS1NSGCT, and may be a new option as initial treatment for all CS1 NSGCT.
Observation versus adjuvant radiation or chemotherapy in the management of stage I seminoma.
TLDR
Consistent with published trials, the data show that adjuvant radiation and chemotherapy yield similar outcomes in the management of stage I seminoma and observation is a viable option that allows patients to avoid the toxicities of therapy.
Optimal management of clinical stage I testis cancer: one size does not fit all.
  • R. de Wit, G. Bosl
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
The optimal management for clinical stage (CS) I testicular germ cell tumors (GCTs) is controversial. Simply put, the efficacy of cisplatin-based chemotherapy cures nearly 100% of both seminoma (SEM)
Management of clinical stage I seminomatous testicular cancer: A report from SWENOTECA.
TLDR
A risk-adapted protocol was initiated in 2007, based on the proposed risk factors; invasion of rete testis and tumor size >4cm and patients with 0-1 risk factor were recommended SURV, but could choose 1 course of AC (AUC7).
Molecular biomarkers as potential targets for therapeutic strategies in human testicular germ cell tumors: An overview
TLDR
A mini‐review will be an overview on the molecular alterations identified in TGCTs and on novel targeted antineoplastic strategies that might help to treat chemotherapy resistantTGCTs.
...
...